Strategies of radioiodine ablation in patients with low-risk thyroid cancer

New England Journal of Medicine

Volumn 366, Issue 18, 2012, Pages 1663-1673

  Schlumberger, Martin ^a   Catargi, Bogdan ^b   Borget, Isabelle ^a   Deandreis, Désirée ^a   Zerdoud, Slimane ^d   Bridji, Boumédiène ^e   Bardet, Stéphane ^f   Leenhardt, Laurence ^g   Bastie, Delphine ⁱ   Schvartz, Claire ^j   Vera, Pierre ^k   Morel, Olivier ^l   Benisvy, Danielle ^m   Bournaud, Claire ⁿ   Bonichon, Françoise ^c   Dejax, Catherine ^o   Toubert, Marie Elisabeth ^h   Leboulleux, Sophie ^a   Ricard, Marcel ^a   Benhamou, Ellen ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c INSTITUT BERGONIÉ   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j INSTITUT JEAN GODINOT   (France)

^k Centre Becquerel   (France)

^l UMR INSERM U892 CNRS 6299   (France)

^m Centre Lacassagne   (France)

ⁿ HOSPICES CIVILS DE LYON   (France)

^o CENTRE JEAN PERRIN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ABLATION THERAPY; ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG EFFICACY; DRUG MEGADOSE; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; THYROID CARCINOMA; TUMOR ABLATION; TUMOR VOLUME;

EID: 84860488883     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1108586     Document Type: Article

References (40)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306. (Pubitemid 28065257)
2. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214. [Erratum, Thyroid 2010;20:674-5.]
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. [Erratum, Eur J Endocrinol 2006;155:385.] (Pubitemid 43997716)
4. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8. (Pubitemid 32268810)
5. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-501.
6. Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008;93:76-81.
7. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-85. (Pubitemid 36920280)
8. Jonklaas J, Cooper DS, Ain KB, et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 2010;20:1423-4.
9. Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009;94:1162-7.
10. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002;87:5817-20. (Pubitemid 36034394)
11. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265-71. (Pubitemid 36459308)
12. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76. (Pubitemid 39089119)
13. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 2007;92:28-38. (Pubitemid 46075005)
14. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84. (Pubitemid 43357753)
15. Mernagh P, Suebwongpat A, Silverberg J, Weston A. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective. Value Health 2010;13:180-7.
16. Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-54. (Pubitemid 46768466)
17. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32. (Pubitemid 43357760)
18. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003;88:4110-5. (Pubitemid 37153707)
19. Rosario PW, Xavier AC. Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131-iodine in low-risk patients. Am J Clin Oncol 2012;35:101-4.
20. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-8.
21. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6. (Pubitemid 47435333)
22. Chianelli M, Todino V, Graziano FM, et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009;160:431-6.
23. Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009; 94:4171-9.
24. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010;20:173-9.
25. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. In: World Health Organization international histological classification of tumours. Berlin: Springer-Verlag, 1988:1-18.
26. Shah JP, Ang KK, Forastiere A, et al. Head and neck sites. In: Greene FL, Page DL, Fleming ID, et al., eds. AJCC cancer staging handbook. 6th ed. Chicago: American Joint Committee on Cancer, 2002:89-98.
27. Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3590-4. (Pubitemid 47435339)
28. Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007;92:2487-95. (Pubitemid 47037347)
29. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010;20:587-95.
30. Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011;96:1352-9.
31. Billewicz WZ, Chapman RS, Crooks J, et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969;38:255-66.
32. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
33. Altman DG, Bland JM. How to randomise. BMJ 1999;319:703-4. (Pubitemid 29423963)
34. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-11. (Pubitemid 36337763)
35. Rosário PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 2008;49:1776-82.
36. Nascimento C, Borget I, Al Ghuzlan A, et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 2011;18:R29-R40.
37. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988-94. (Pubitemid 47611686)
38. 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005;90:1440-5.
39. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139:346-51.
40. Mallick U. HiLo: multicentre randomised phase III clinical trial of high versus low dose radioiodine, with or without recombinant thyroid stimulating hormone (rhTSH) for remnant ablation for differentiated thyroid cancer. In: Program and abstracts of the 14th International Thyroid Congress, Paris, September 11-16, 2011. abstract.